|Bid||35.36 x 900|
|Ask||40.00 x 1100|
|Day's Range||35.31 - 35.88|
|52 Week Range||33.51 - 68.55|
|Beta (3Y Monthly)||1.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.86|
NEW YORK, NY / ACCESSWIRE / May 15, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") ...
FibroGen news has FGEN stock down on Friday after releasing confusing results from a recent trial.Source: Shutterstock The report from FibroGen (NASDAQ:FGEN) has to do with its Roxadustat drug for treating kidney disease. The statements made by the company in this update weren't exactly clear. This includes "we believe there is no clinically meaningful difference in risk."These unclear statements from the company were able to give some investors doubts about the drug. However, it looks like the results are better than expected. It was just the wording in the FibroGen news release that was causing problems.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"There is confusion in the market currently, but this should become clear as more investors realize the data is positive and Roxa's risk/benefit is favorable, so we see the stock rebounding and moving back up over time," Jefferies analysts said in a statement obtained by FierceBiotech.The FibroGen news about Roxadustat comes in the company's earnings report for the first quarter of 2019. The poor wording and confusion was also dragging down an otherwise solid earnings report. * 7 Cloud Stocks to Buy on Overcast Days FibroGen reported losses per share of 53 cents on revenue of $23.86 million. Losses per share and revenue from the same time last year were 50 cents and $31.93 million. Wall Street was looking for the company to reported losses per share of 67 cents on revenue of $20.00 million.FGEN stock was down 24% as of noon Friday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Cloud Stocks to Buy on Overcast Days * 6 Stable Stocks Worth Buying for Protection * 5 Active Vanguard Funds That You Have to Own As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post FibroGen News: Why FGEN Stock Is Plummeting Today appeared first on InvestorPlace.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 9) Alcon AG (NYSE: ALC ) ANI Pharmaceuticals Inc (NASDAQ: ...
FibroGen (FGEN) delivered earnings and revenue surprises of 22.06% and 19.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Francisco-based company said it had a loss of 53 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Positive topline results from pooled safety analyses of roxadustat Phase 3 global programCompleted one year of treatment in Phase 2 trial evaluating pamrevlumab in treatment of.
FibroGen, Inc. (FGEN) today announced topline results from the pooled safety analyses of the global Phase 3 program for roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity (HIF-PHI). The global pivotal Phase 3 trials were conducted by FibroGen and collaboration partners AstraZeneca and Astellas Pharma, Inc., for treatment of anemia in chronic kidney disease (CKD) patients across the non-dialysis-dependent (NDD), incident (newly initiated) dialysis, and dialysis-dependent (DD) CKD populations, enrolled from more than 50 countries.
FibroGen Inc NASDAQ/NGS:FGENView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.14 billion over the last one-month into ETFs that hold FGEN are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SAN FRANCISCO, May 06, 2019 -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019 after market.
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in FibroGen, Inc. (NASDAQ:FGEN) then it's worth thinking about how it contributes t...
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 15 S&P 500 stocks […]
This week's Health Care Digest explores growing companies and introduces our new health care reporter, Hannah Norman.
“We are pleased to have received Orphan Drug Designation from the FDA for pamrevlumab in the treatment of DMD. There is high unmet medical need for patients suffering from this debilitating disease needing a new treatment option,” said Elias Kouchakji, M.D., Senior Vice President, Clinical Development and Drug Safety. “All 21 non-ambulatory DMD patients in our ongoing phase 2 study with pamrevlumab have completed the first 52 weeks of treatment.
Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like FibroGen, Inc. (NASDAQ:F...